This trial will study the effects of SGLT2i drugs (which cause increased ketone levels in the blood) on various measures of health, including muscle and heart function, exercise capacity, and quality of life.
- Diastolic Heart Failure
- Type 2 Diabetes
5 Primary · 5 Secondary · Reporting Duration: Baseline to 3 months
Side Effects for
2 Treatment Groups
1 of 2
1 of 2
30 Total Participants · 2 Treatment Groups
Primary Treatment: Empagliflozin 25 MG · Has Placebo Group · Phase < 1
Who is running the clinical trial?
Age 18 - 80 · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is participation in this research still open to new subjects?
"This clinical trial is aiming to enrol 30 subjects who suffer from heart failure with preserved ejection fraction and are between 18 - 80 years of age." - Anonymous Online Contributor
Is this the inaugural instance of such a clinical trial?
"Empagliflozin 25 MG has been subject to scientific research since 2018, when Boehringer Ingelheim sponsored its first trial with 175 participants. Following the successful Phase 3 drug approval in that year, there are currently 49 active studies spanning 237 cities and 43 nations worldwide." - Anonymous Online Contributor
Are there still vacancies for individuals to take part in this investigation?
"The trial is still open for recruitment, per the data available on clinicaltrials.gov. The medical research was first released to the public in January 2021 and had its latest update earlier this November 2022." - Anonymous Online Contributor
Are elderly individuals being considered for participation in this trial?
"The conditions for enrollment in this medical trial necessitate that the patient is between 18 and 80 years old. There are 28 different trials available to patients below legal age, with 783 studies geared towards individuals over 65." - Anonymous Online Contributor
What is the scope of the investigation into this therapy?
"Yes, as per the information on clinicaltrials.gov, this research endeavour is currently open for enrolment. It was first published on January 13th 2021 and has been updated most recently November 7th 2022. This trial seeks to have 30 participants from two separate locations." - Anonymous Online Contributor
What is the empirical evidence regarding Empagliflozin 25 MG?
"Currently, 49 clinical trials are being conducted for the 25 MG dosage of Empagliflozin. Of these experiments, 13 have reached Phase 3 status. While Rosario in British Columbia holds a majority of the studies related to this medication, there is still research taking place at 1,012 venues worldwide." - Anonymous Online Contributor
To what conditions is Empagliflozin 25 MG typically prescribed?
"Empagliflozin 25 MG is a useful therapeutic option for treating various heart-related conditions, including cardiovascular mortality, heart failure, and type 2 diabetes mellitus." - Anonymous Online Contributor
What are the underlying goals of this research endeavor?
"The primary goal of this experiment, to be monitored from the start until 3 months later, is an alteration in Phosphodiester levels. Additionally, Cardiopulmonary Function (Change in oxygen uptake or VO2), Plasma Beta-hydroxybutyrate (β-OH-B) intensity (Change in β-OH-B) and 6 minute walk test performance (Distance covered over a 6 minute period) will all be measured as secondary objectives." - Anonymous Online Contributor